SanBio Company (4592) Q1 2026 earnings summary

Executive summary

• Focused on commercializing AKUUGO®, a regenerative medicine product for chronic motor paralysis from traumatic brain injury, with Japanese regulatory approval received and shipments expected to begin in Q2 FY2026 (May–July 2025).

• Strategic emphasis on expanding clinical trials for chronic ischemic stroke and traumatic brain injury in the US and Japan, aiming for global leadership in regenerative medicine.

Financial highlights

• Operating loss of ¥1,007 million for Q1 FY2026, compared to ¥666 million loss in the same period last year.

• Ordinary loss of ¥1,750 million, reversing from ¥91 million ordinary income year-over-year.

• Net loss attributable to owners of parent was ¥1,531 million, compared to ¥144 million net loss year-over-year.

• Research and development expenses totaled ¥723 million, mainly for AKUUGO® approval-related activities.

• Foreign exchange losses of ¥711 million significantly impacted non-operating expenses.

Outlook and guidance

• No revisions to the previously released consolidated financial results forecast for FY2026.

• Full-year net loss forecasted at ¥3,554 million, with net loss per share of ¥49.41.

• No dividend payments planned or forecasted for the fiscal year.